InvestorsHub Logo
Followers 10
Posts 1578
Boards Moderated 0
Alias Born 10/15/2014

Re: turks post# 12396

Tuesday, 10/17/2017 6:18:34 PM

Tuesday, October 17, 2017 6:18:34 PM

Post# of 16885
It depends on whether Trump follows what the Commission recommends in its report. Now that Tom "MAT is using a drug to fight a drug" Price is gone, I think chances are he will.

The interim report highlights the early conclusions.

https://www.whitehouse.gov/sites/whitehouse.gov/files/ondcp/commission-interim-report.pdf

My favorite parts:

Immediately Establish and Fund a Federal Incentive to Enhance Access to Medication Assisted Treatment. Speaks for itself…the Senate almost approved a $45 billion over ten year fund as part of the healthcare legislation.

Require that all modes of MAT are offered at every licensed MAT facility, and that those decisions are based on what is best for the patient. Right now, the Vivitrol doctors only sell Vivitrol, and the Suboxone doctors only sell Suboxone, etc. This would require all potential modes of MAT to be offered to each patient, allowing for a customized recovery plan. Probuphine is good, but it’s not for everyone. Same for Vivitrol and Suboxone (and the injectables when they are approved). This should increase awareness of probuphine and help with sales (remember, they are only shooting for 2-5% of the market).

Enforcing the Mental Health Parity and Addiction Equity Act: Basically, requiring insurers to follow the law, which states they cannot impose less favorable benefits for mental health/addiction diagnoses vs. physical health diagnoses. If a doctor diagnoses someone as having a life threatening physical health condition (e.g., anneursym, heart attack, late stage cancer), they don’t have to wait for weeks for prior authorization from an insurance company before they treat the patient. Not so with addiction, and so changing that practice should make sales of probuphine grow.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TTNP News